Spots Global Cancer Trial Database for Bevacizumab (Avastin) and RAD001(Everolimus)in the Treatment of Advanced Clear Cell Renal Carcinoma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Bevacizumab (Avastin) and RAD001(Everolimus)in the Treatment of Advanced Clear Cell Renal Carcinoma
Official Title: Phase II Trial of Bevacizumab(Avastin) and RAD001(Everolimus)in the Treatment of Patients With Advanced Clear Cell Renal Carcinoma
Study ID: NCT00323739
Conditions
Study Description
Brief Summary: This phase II trial will evaluate the combination of bevacizumab + RAD001 in patients with metastatic renal cell carcinoma. In this trial the investigators will evaluate this combination in patients previously untreated with any anti-angiogenesis agent and patients who have previously received one prior regimen containing an anti-angiogenesis agent.
Detailed Description: All eligible patients will receive: * Bevacizumab 10mg/kg, IV infusion, every 2 weeks * RAD001 10 mg by mouth daily All patients will be evaluated for response after completing two courses (8 weeks) of treatment. Patients with objective tumor response or stable disease will continue treatment with bevacizumab adn RAD001 on the same schedule. Treatment will continue until disease progression occurs.
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Florida Cancer Specialists, Fort Myers, Florida, United States
Gainsville Hematology Oncology Associates, Gainesville, Florida, United States
Integrated Community Oncology Network, Jacksonville, Florida, United States
Florida Hospital Cancer Institute, Orlando, Florida, United States
Wellstar Cancer Research, Marietta, Georgia, United States
Consultants in Blood Disorders and Cancer, Louisville, Kentucky, United States
Baton Rouge General Medical Center, Baton Rouge, Louisiana, United States
Grand Rapids Clinical Oncology Program, Grand Rapids, Michigan, United States
Methodist Cancer Center, Omaha, Nebraska, United States
Oncology Hematology Care, Cincinnati, Ohio, United States
Chattanooga Oncology Hematology Associates, Chattanooga, Tennessee, United States
Tennessee Oncology, PLLC, Nashville, Tennessee, United States
Contact Details
Name: John D. Hainsworth, MD
Affiliation: SCRI Development Innovations, LLC
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
